Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$3.35 $3.09

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 67,855 66,398

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 75,580 78,814

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($77.0 million in 2008; $64.2 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($5.4 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) To exclude charges related to payments for several research and development collaborations ($6.0 million in 2008; $26.5 million in 2007), other charges related to employee severance costs ($1.8 million in 2008), and accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($0.3 million in 2008). In 2007, we also excluded the recognition of a milestone ($15.0 million) related to the FDA's acceptance of our NDA filing for TREANDA.

(3) To exclude charges related to employee severance costs ($3.0 million) and charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc. ($27.2 million).

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the pre-tax gain related to the sale of certain investments.

(6) To exclude the forgiveness of a mortgage loan by the PIDA.

(7) To exclude the accrued int
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... SAN FRANCISCO, Nov. 2, 2011 Jennerex, Inc., a ... commercialization of first-in-class targeted oncolytic products for cancer, today ... clinical trial in advanced liver cancer patients will be ... Annual Meeting of the American Association for the Study ...
... a premature ageing disease that affects children causing them to ... rate. The study is the first to outline how ... could provide a model for understanding processes that cause us ... such as reducing degeneration of some tissues in older age, ...
... World, Paul Blom and Ton van Mol from the ... thin, flexible sheets of organic light-emitting diodes (OLEDs) using ... bendable materials could oust the conventional light bulb and ... for everything from lighting tiles and strips in homes ...
Cached Biology Technology:Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 2Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 3Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 4Cellular repair could reduce premature aging 2Cellular repair could reduce premature aging 3Researchers roll out a new form of lighting 2
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has launched an ... tissue that enhances care coordination among social service and care ... a second $1 million grant from the Alliance Healthcare Foundation ... will be recognized as a "Live Well San Diego" partner ...
(Date:12/10/2014)... 2014     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... at Rice University, has been awarded the prestigious Foresight ... the California think tank dedicated to the beneficial implementation ... for the prize, specifically for his work on the ... served as an experiment to explore the possibility of ...
... American Society for Microbiology (ASM) has been honored with ... of its public outreach initiatives. The awards were ... The Society,s MicrobeWorld Video series received the award for ... video series strives to increase public understanding and appreciation ...
... 16, 2008Once believed to be important only for bone ... critical function in maintaining the immune system throughout life. ... deficiency are clearly documented in a report in the ... Medicine , a peer-reviewed journal published by Mary Ann ...
Cached Biology News:Rice's James Tour wins Feynman Prize 2Vitamin D deficiency in infants and nursing mothers carries long-term disease risks 2
... Rotofor purification system, 100-120 V, is used ... isoelectric focusing (IEF). The system includes both ... ml) focusing chambers, chassis, harvesting apparatus, cooling ... (pH 3-10), 60 ml syringe, colored protein ...
...
... B-Phycoerythrin Labeling Kit - NH2 is primarily ... for immunostaining and cellular proteins for tracing. ... has succinimidyl group (NHS), and can easily ... of IgG or other proteins without any ...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Biology Products: